Document is current
Any future updates will be listed below
-
Authors
Bi, Mingjun https://orcid.org/0000-0001-8748-2636
Zhang, Zhao https://orcid.org/0000-0002-3679-8945
Jiang, Yi-Zhou
Xue, Pengya https://orcid.org/0000-0002-5887-1760
Wang, Hu
Lai, Zhao
Fu, Xiaoyong https://orcid.org/0000-0003-0005-6496
De Angelis, Carmine https://orcid.org/0000-0003-1158-4630
Gong, Yue
Gao, Zhen
Ruan, Jianhua
Jin, Victor X.
Marangoni, Elisabetta
Montaudon, Elodie
Glass, Christopher K.
Li, Wei https://orcid.org/0000-0001-9931-5990
Huang, Tim Hui-Ming
Shao, Zhi-Ming
Schiff, Rachel https://orcid.org/0000-0003-1696-5213
Chen, Lizhen https://orcid.org/0000-0001-5313-7340
Liu, Zhijie https://orcid.org/0000-0001-6956-7839
-
Funding
Funding for this research was provided by:
Cancer Prevention and Research Institute of Texas (RR160017)
V Foundation for Cancer Research (V2016-017)
V Foundation for Cancer Research (DVP2019-018)
Susan G. Komen (CCR17483391)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U54 CA217297/PRJ001)
Max and Minnie Tomerlin Voelcker Fund (Young Investigator Award)
- License Information
-
More Information
Article History
Received: 14 May 2019
Accepted: 30 March 2020
First Online: 18 May 2020
Competing interests
: R.S. has received research support from AstraZeneca, GlaxoSmithKline, Gilead and Puma Biotechnology, served as a consultant to Eli Lilly, and is a consultant/advisory board member for MacroGenics. All other authors declare no competing interests.
